Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.

Also called NCT01382277

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01382277
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01382277. Allocation not applicable; no masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2013-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume
Acronym
REDUCT
Condition
Hyperlipidemia
Intervention (Drug)
Rosuvastatin
Lead sponsor
Peking University First Hospital (class: other)

Record details

Record id
cardio:ct-nct01382277
Content hash
a910aaea71860129e020031fb8768d4fc0b56b47a9325990506a9a561fcd1338